Vertex Pharmaceuticals Incorpor (VRTX) is currently trading at $526.19. Based on 28 Wall Street analysts, the average target price is $570.32, implying a 8.4% upside. The consensus recommendation is BUY.
No firm-level price target raises or cuts for VRTX are recorded in the past 30 days. Over the past 90 days, the feed records 9 target raises and 0 target cuts for VRTX.
Vertex Pharmaceuticals Incorpor
Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).
Price (USD)
Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price
| Firm | Date | PT action | Prior → Current |
|---|---|---|---|
| Truist Securities | Aug 5, 2026 | Raises | $560.00 → $565.00 |
| Barclays | Aug 5, 2026 | Raises | $615.00 → $617.00 |
| TD Cowen | Aug 4, 2026 | Raises | $525.00 → $550.00 |
| Cantor Fitzgerald | Aug 4, 2026 | Raises | $590.00 → $595.00 |
| Canaccord Genuity | Aug 4, 2026 | Raises | $436.00 → $442.00 |
| UBS | Jul 13, 2026 | Raises | $545.00 → $585.00 |
| Truist Securities | Jul 13, 2026 | Raises | $542.00 → $560.00 |
| RBC Capital | Jul 7, 2026 | Raises | $543.00 → $570.00 |
| Baird | Jul 7, 2026 | Raises | $330.00 → $350.00 |
| Barclays | May 6, 2026 | Raises | $607.00 → $615.00 |
| Canaccord Genuity | May 5, 2026 | Lowers | $437.00 → $436.00 |
| Morgan Stanley | May 5, 2026 | Raises | $612.00 → $616.00 |
| Bernstein | May 5, 2026 | Lowers | $577.00 → $572.00 |
| RBC Capital | May 5, 2026 | Raises | $541.00 → $543.00 |
| Canaccord Genuity | Apr 30, 2026 | Lowers | $441.00 → $437.00 |
| Morgan Stanley | Apr 10, 2026 | Raises | $596.00 → $612.00 |
| Maxim Group | Mar 18, 2026 | Announces | $0.00 → $575.00 |
| Truist Securities | Mar 11, 2026 | Raises | $490.00 → $525.00 |
| Morgan Stanley | Mar 10, 2026 | Raises | $570.00 → $596.00 |
| B of A Securities | Mar 10, 2026 | Raises | $571.00 → $598.00 |
PT action: Raises
$560.00 → $565.00
PT action: Raises
$615.00 → $617.00
PT action: Raises
$525.00 → $550.00
PT action: Raises
$590.00 → $595.00
PT action: Raises
$436.00 → $442.00
PT action: Raises
$545.00 → $585.00
PT action: Raises
$542.00 → $560.00
PT action: Raises
$543.00 → $570.00
PT action: Raises
$330.00 → $350.00
PT action: Raises
$607.00 → $615.00
PT action: Lowers
$437.00 → $436.00
PT action: Raises
$612.00 → $616.00
PT action: Lowers
$577.00 → $572.00
PT action: Raises
$541.00 → $543.00
PT action: Lowers
$441.00 → $437.00
PT action: Raises
$596.00 → $612.00
PT action: Announces
$0.00 → $575.00
PT action: Raises
$490.00 → $525.00
PT action: Raises
$570.00 → $596.00
PT action: Raises
$571.00 → $598.00
Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.
$570.32
Based on 28 analysts
+8.39%
$133.37B
Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.
No major insider buying detected recently.
| Date | Name | Position | Transaction | Shares |
|---|---|---|---|---|
| 7/2/2026 | MCKECHNIE DUNCAN J. | Officer | Sale at price 519.00 per share. | 1,541 |
| 7/2/2026 | TATSIS OURANIA | Officer | Sale at price 524.99 per share. | 1,500 |
| 7/1/2026 | LIU JOY | Officer | Sale at price 502.71 per share. | 828 |
| 6/26/2026 | BOZIC CARMEN | Officer | Sale at price 482.50 per share. | 596 |
| 6/18/2026 | BOZIC CARMEN | Officer | Sale at price 462.17 per share. | 1,020 |
| 6/15/2026 | BOZIC CARMEN | Officer | Sale at price 450.00 per share. | 4,062 |
| 6/5/2026 | BOZIC CARMEN | Officer | Sale at price 450.00 per share. | 1,745 |
| 6/1/2026 | LIU JOY | Officer | Sale at price 439.91 per share. | 828 |
| 5/29/2026 | BOZIC CARMEN | Officer | Sale at price 450.00 per share. | 1,974 |
| 5/15/2026 | BUNNAGE MARK E. | Officer | Sale at price 453.45 per share. | 33 |
A. The current target price for Vertex Pharmaceuticals Incorpor is $570.32, which implies a 8.4% upside from the current price of $526.19. This is based on the consensus of 28 Wall Street analysts.
A. Currently, there are 6 Strong Buy, 20 Buy, 4 Hold, 1 Sell, and 1 Strong Sell ratings. The overall consensus is BUY.
A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.
Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.
Read full disclaimer →